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Abstract
Purpose: Salvage surgery of recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) results in
limited local control and survival rates. As a result of recent technological progress, radiotherapy (RT) has become a
valuable, potentially curative therapeutic option. Thus, we aimed to determine prognostic factors for survival
outcome in order to optimize patient selection for salvage radiotherapy after failure of first-line treatment with
surgery alone in this special patient cohort.
Methods: Seventy-five patients (85% male, median age of 64 years) underwent salvage RT in a secondary setting
for recurrent hypopharyngeal or laryngeal SCC after prior surgery alone between 2007 and 2017. On average,
patients were treated with one prior surgery (range 1–4 surgeries). Median time between surgery and salvage RT
was 7 months (range 1–47 months) for initially advanced tumors (T3/4, N+, extracapsular spread) and 18 months
(range 5–333 months) for initially early stage tumors. The majority of patients received concomitant chemotherapy
(n = 48; 64%) or other kind of systemic treatment concurrent to radiotherapy (n = 10; 13%).
Results: Median follow-up was 41 months (range 3–120 months). Overall, fifteen patients were diagnosed with local
failure (all were in-field) at last follow-up (20%). Median time to recurrence was 35 months (range 3–120 months)
and 3-year local progression-free survival (LPFS) was 75%, respectively. Dose-escalated RT with 70.4 Gy applied in 2.
1 Gy or 2.2 Gy fractions corresponding an EQD2 > 70 Gy (p = 0.032) and the use of concomitant cisplatin weekly
chemotherapy (p = 0.006) had a significant positive impact on LPFS. 3-year OS and DPFS were 76 and 85%,
respectively. No toxicity-related deaths occurred. Reported grade > 3 side effects were rare (n = 4/70, 6%).
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Conclusion: Salvage radiotherapy resulted in excellent local control rates while radiation dose and the use of
cisplatin weekly chemotherapy were identified as prognostic factors for LPFS. Nevertheless, patient selection for
curative salvage treatment remains challenging.
Keywords: Squamous cell carcinoma, Recurrent hypopharynx and larynx carcinoma, Salvage radiotherapy, Function
preservation
Background
Squamous cell carcinoma (SCC) of the larynx and hypo-
pharynx is the most common tumor in the head and neck
region, mainly observed in males over 50 years. Especially
glottic larynx carcinomas are mostly diagnosed in early
stages due to the disorder of essential laryngeal and hypo-
pharyngeal functions presenting with initial symptoms, i.e.
hoarseness, swallowing difficulties or dyspnea, resulting in
significant reduced patient′s satisfaction and quality of life
[1–3]. Therefore, besides achieving optimum local control,
preservation of phonatory and swallowing function gain in
importance. The role of chemoradiotherapy (CRT) in the
organ-preserving treatment of hypopharyngeal and laryn-
geal malignancies was established by two important land-
mark trials, showing equal survival rates compared with
surgery and a high rate of larynx-preservation in two-
thirds of the patients [4, 5]. Over the last two decades,
CRT is increasingly considered as a valuable alternative to
total laryngectomy for advanced tumors. Nowadays, total
laryngectomy is mostly used in highly selected patients
with advanced diseases or reserved as salvage surgery in
case of treatment failure after primary CRT. In the current
literature, poor prognosis is reported for patients who
were treated with salvage surgery after radiotherapy failure
in several studies [6, 7]. However, data concerning out-
come of salvage CRT after failed first-line surgical treat-
ment are still missing. The aim of this retrospective
analysis is to assess clinical outcome in patients with re-
current hypopharyngeal and laryngeal SCC after first-line
treatment with surgery alone, who received second-line
RT in potentially curative intention and to determine
prognostic factors for survival outcome to optimize pa-
tient selection for salvage radiotherapy.
Materials and methods
Evaluation
Seventy-five patients with laryngeal or hypopharyngeal
SCC treated for recurrence after prior surgery at the
Department of Radiation Oncology of the University
Hospital Heidelberg between 2007 and 2017 were identi-
fied retrospectively and patient′s records were analysed
regarding local progression-free survival (LPFS), overall
survival (OS) and distant progression-free survival (DPFS).
Additionally, potential prognostic factors were assessed
and calculated for local control (LC), OS and DPFS.
Follow-up was performed with magnetic resonance
imaging (MRI) or computed tomography (CT) 6 weeks
after completion of therapy, at three-month intervals
during the first 2 years after treatment, every 6 months
during the third year after treatment and then, once a
year. Yearly CT scans of the chest and abdominal ultra-
sound were performed to identify distant relapse.
Acute and late toxicity were assessed according to the
Common Terminology Criteria for Adverse Events ver-
sion 4.03 (CTCAE v4.03) and tumor response to the
current Response Evaluation Criteria in Solid Tumors
(RECIST) [8, 9]. TNM (tumor, nodal, metastasis) stage
was assessed and adjusted to the eight edition of the TNM
classification system [10].
Survival data were calculated from first diagnosis to
the date of last follow-up, death or progression by using
Kaplan-Meier estimates (IBM SPSS Statistics version
24). OS was calculated from the first diagnosis up to
the last follow-up or death. LPFS and DPFS were con-
sidered as the time period between first diagnosis and
occurrence of local progression, distant progression or
death. LC was calculated from first day of treatment to
last follow-up or local progression. Univariate analysis
to identify potential prognostic factors for survival out-
come were performed using the log-rank test. For
multivariate analysis, the cox regression model was
used. All tests were 2-tailed and the significance level
was defined as ∝ < 0.05.
Patient characteristics
All patients received RT in a secondary setting for recur-
rence after first-line treatment with surgery alone (median
number of operations 1, range 1–4). Patients who received
a prior radiation treatment were excluded from the study.
Initially, postoperative RT (n = 13, 17%) for UICC stage
III/IV or CRT (n = 22, 29%) for incomplete resection mar-
gin (n = 11, 15%), lymph node metastases with extracapsu-
lar spread (ECS; n = 9, 12%) or both (n = 2, 3%) was
obligatory in overall 47% of the patients but was declined
from the patient. Therefore, two treatment groups were
differed within the study population; early stage patients
without an initial indication for postoperative RT (n = 40,
53%) and patients with advanced tumors who declined
postoperative RT after first-line surgery (n = 35, 47%).
Prior total laryngectomy was performed in 24% of the
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patients (n = 18), prior unilateral neck dissection (ND) in
9% of the patients (n = 7) and bilateral ND in 35% of the
patients (n = 26). In 79%, lymph node metastases could be
identified (n = 26), in 11/26 patients with ECS (for detailed
treatment characteristics please see Table 2).
The majority of the patients were male (n = 64, 85%)
and older than 60 years (n = 45, 60%) at RT initiation
(median age of 64 years, range 46–83 years). The most
common initial tumor sites were the glottic larynx with
61% (n = 46), the hypopharynx with 19% (n = 14) and
the supraglottic larynx with 16% (n = 12). Regarding the
recurrent tumor sites after prior surgery, the glottic lar-
ynx (n = 31, 41%), the neopharynx (n = 12, 16%) and the
hypopharynx (n = 14, 19%) dominated. At first diagno-
sis, 56% of the tumors were at UICC stage I-II (n = 44).
At recurrence, higher UICC stages could be identified
with 28% for UICC stage III (n = 21), 25% for UICC
stage IVA (n = 19), 13% for UICC stage IVB (n = 10)
and 1% for UICC stage IVC (n = 1). Patient characteris-
tics are shown in Table 1.
Treatment characteristics
For treatment planning, CT and MRI were performed and
patients were immobilized with custom-made thermoplas-
tic masks with shoulder fixation. Clinical target volume 1
(CTV1) including the macroscopic tumor and the poten-
tial microscopic spread and CTV2 including the CTV1
and the lymphatic drainage were outlined. Planning target
volumes (PTVs) were generated with a margin of 5mm
around the CTVs and received at least 90% of the pre-
scription dose. All patients received intensity modulated
radiotherapy (IMRT) via tomotherapy with (n = 70, 93%)
or without simultaneous integrated boost (SIB, n = 5, 7%)
at a median time of 7 months after the first operation
(range 1–333months). Single doses and prescription doses
differed, thus we calculated the equivalent dose in 2 Gy
per fraction with the following formula for better dose
comparibility: EQD2 =D x ((d + α/β)/(2 + α/β)) (D = total
dose in Gy, d = single dose in Gy, α/β = 2).
The median prescribed total dose was 54 Gy (range
52.2–66 Gy) with a median single dose fraction of 1.8
Gy (range: 1.8–2.0 Gy) to the bilateral cervical lymph
drainage and 66 Gy (range 58–72 Gy) with a median
single dose fraction of 2.2 Gy (range 1.8–2.2 Gy) to the
macroscopic tumor. The median equivalent dose to a 2
Gy single dose fraction (EQD2) prescribed on the
macroscopic tumor was 67 Gy (range 60–73 Gy). In 5
cases, treatment could not be finished (7%). Thus, these
patients received smaller cumulative doses. The median
PTV1 was 101 cc (range 21–222 cc) and the median
PTV2 was 740 cc (range 51–1301 cc). Overall, 77% of
the patients were treated with concomitant systemic
therapy (n = 58) of whom 64% received concomitant
chemotherapy (n = 48) with carboplatin/5-fluoruracil in
week 1 and 5 (n = 4) or cisplatin weekly (n = 44) and
13% concomitant immunotherapy with cetuximab
weekly (n = 10). Treatment characteristics are depicted
in Table 2.
Results
Survival analysis
Five patients could not finish therapy for deterioration
of their general condition (KPS < 60%) and were lost to
follow-up after treatment. Therefore, we excluded these
patients from the analysis (7%). Median follow-up for
all remaining patients was 41 months (range 8–120
months) and for surviving patients 50 months (range
8–120 months). At last follow-up, 56% of the patients
were still alive (n = 39) of whom 87% were free of local
failure (n = 34). Median OS from first diagnosis up to
last follow-up or death was 59 months (range 11–373
months) and from RT up to last follow-up or death 43
months (range 14–121 months). Overall, complete re-
mission was seen in 48 patients (64%) and partial
remission in six patients (8%). 20% of the patients de-
veloped an in-field recurrence (n = 14) and one patient
a locoregional recurrence in cervical lymph nodes (1%)
after a median time of 12 months (range 3–19 months)
after RT. All local and locoregional recurrences oc-
curred within the first 2 years after RT. Distant metas-
tases (n = 13) were diagnosed in 19% of the patients
after a median time of 28 months (range 2–88 months)
after the first diagnosis with pulmonary failure in 11
cases (16%) and bone metastases in 2 cases (3%). Corre-
sponding 3-year and estimated 5-year LPFS, OS and
DPFS were 75, 76, 85 and 75%, 64, 82% for all patients
without significant differences for initially early stage
(without an initial indication for adjuvant RT) vs. ad-
vanced stage (with an initial indication for adjuvant RT)
larynx/hypopharynx tumors in the LPFS (p = 0.431; HR
= 1.12; 95%-CI = 0.38–21.30), OS (p = 0.518; HR = 0.89;
95%-CI = 1.24–12.46) and DPFS (p = 0.081; HR = 3.04;
95%-CI = 1.98–8.34), respectively. Patients with local or
locoregional recurrence received either palliative sys-
temic therapy (n = 5, 7%), best supportive care (n = 1,
1%), salvage larynx-preserving surgery (n = 2, 3%), sal-
vage ND (n = 1, 1%), salvage total laryngectomy (n = 5,
7%) or re-RT (n = 1, 1%). Thus, preservation of the lar-
ynx could be achieved in 90% (n = 47/52) of the patients
apart from patients who were initially treated by total
laryngectomy.
Prognostic factors for survival
We analysed the impact of potential prognostic factors at
time of first-line treatment with surgery alone (initial T, N,
G stage, ECS, tumor site, Karnofsky performance status
(KPS), prior laryngectomy vs. larynx-preserving surgery,
prior ND yes vs. no, time period between first operation
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and first recurrence) and at time of second-line treatment
with salvage RT (recurrent T, N, G stage, KPS, number of
prior operations, EQD2 > 70Gy vs. ≤70Gy, PTV1 ≥ 101 cc
vs. < 101 cc, cisplatin weekly chemotherapy vs. others,
local recurrences yes vs. no after RT and metastases yes
vs. no) on OS, LPFS and DPFS. Several potential prognos-
tic factors were identified using the log-rank test for uni-
variate analyses. Independent prognostic factors were
assessed by the cox regression model for multivariate ana-
lysis. The results of univariate and multivariate analysis
are shown in Table 3.
Regarding LPFS, we could identify the use of concomi-
tant chemotherapy with cisplatin weekly (p = 0.006) and
an EQD2 > 70Gy prescribed on the macroscopic tumor
as positive prognostic factors (p = 0.032). Patients who
received concomitant systemic therapy were included
into analysis only. The use of concomitant chemother-
apy with cisplatin weekly resulted in a 5-year LPFS of
86% vs. 44% compared with patients who received con-
comitant chemotherapy with carboplatin/5-FU in week 1
and 5 or cetuximab weekly (Fig. 1). With regard to the
applied EQD2 on the macroscopic recurrent tumor, pa-
tients who received an EQD2 > 70 Gy had a 5-year LPFS
of 90% vs. 68% compared with patients who received an
EQD2 ≤ 70 Gy (Fig. 2).
Table 1 Patient and tumor characteristics at first-line and
second-line treatment, n = 75
characteristic No. (%)
first-line treatment
(surgery)
second-line treatment
(RT/CRT)
median age (years) 59 (42–83) 62 (46–83)
gender
male 64 (85) 64 (85)
female 11 (15) 11 (15)
Karnofsky performance
score in %
100 25 (33) 12 (16)
90 18 (24) 23 (31)
80 24 (32) 17 (23)
70 8 (11) 17 (23)
60 none 6 (8)
tumor site
glottic larynx 46 (61) 31 (41)
subglottic larynx 3 (4) 10 (13)
supraglottic larynx 12 (16) 8 (11)
hypopharynx 14 (19) 14 (19)
neopharynx none 12 (16)
UICC stage
I 20 (27) 16 (21)
II 22 (29) 8 (11)
III 9 (12) 21 (28)
IVA 22 (29) 19 (25)
IVB 1 (1) 10 (13)
IVC 1 (1) 1 (1)
TNM stage
T1 22 (29) 22 (29)
T2 25 (33) 12 (16)
T3 14 (19) 15 (20)
T4 14 (19) 26 (35)
N0 51 (68) 48 (64)
N1 3 (4) 11 (15)
N2 20 (27) 14 (19)
N3 1 (1) 1 (1)
M0 74 (99) 73 (97)
M1 1 (1) 2 (3)
G stage
G1 2 (3) 2 (3)
G2 51 (68) 49 (65)
G3 19 (25) 21 (28)
Gx 3 (4) 3 (4)
abbreviations: RT radiotherapy, CRT chemoradiotherapy, T tumor stage, N nodal
stage, M metastasis stage, G grading, UICC Union Internationale Contre
le Cancer
Table 2 Treatment characteristics at first-line and second-line
treatment, n = 75
first-line treatment (surgery)
number of previous surgeries
1 46 (61)
2 17 (23)
3 10 (13)
4 2 (3)
total laryngetomy 18 (24)
larynx-preserving surgery 57 (76)
vocal cord tripping 2 (3)
endoscopic laser resection 21 (28)
partial laryngectomy 34 (45)
unilateral ND 10 (13)
bilateral ND 27 (36)
ECS 11 (30)
second-line treatment (RT/CRT)
median EQD2 in Gy 67 Gy (60–72 Gy)
median PTV1 101 cc (21–1949 cc)
median PTV2 740 cc (51–72 cc)
concomitant chemotherapy 48 (64)
concomitant cetuximab 10 (13)
abbreviations: RT radiotherapy, CRT chemoradiotherapy, ECS extracapsular
spread, EQD2 equivalent dose in 2 Gy single dose fractions, ND neck
dissection, PTV planning target volume
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Patients with local or locoregional recurrence after sal-
vage RT had a significant worse OS with a 5-year OS of
25% vs. 74% estimated from Kaplan-Meier analysis com-
pared with patients who were free from recurrence at last
follow-up (p = 0.041), respectively. Furthermore, recurrent
tumor site showed an estimated impact on patients′ OS.
Thus, patients with glottic recurrence had a survival bene-
fit with a 5-year OS rate of 89% compared with patients
who had recurrences in the area of the supraglottic or
subglottic larynx, hypopharynx or neopharynx with a
5-year OS rate of 25% (p = 0.05). Additionally, initial N
stage seemed to have a further impact on OS with a sur-
vival benefit for patients without initial lymph node
metastases, but in the multivariate analysis, the signifi-
cance level could not be achieved (p = 0.06).
In terms of DPFS, recurrent T stage showed the most
significant impact on DPFS with a 5-year DPFS of 90%
for rT1/2 tumors and 70% for rT3/4 tumors (p = 0.028).
Further, PTV1 (≥ median of 101 cc vs. < median of 101
cc) had a worse impact on DPFS with increasing volume
(p = 0.038). At least, initial N stage could be diagnosed
as further prognostic factor for DPFS with a significant
Table 3 Results (n = 70)
characteristics 5-year
survival
univariate analysis multivariate analysis
HR (95%-KI) p value HR (95%-KI) p value
overall survival
at first-line treatment (surgery)
iT stage (T3/4 vs. T1/2) 45% vs. 72% 1.46 (1.01–2.11) 0.041
iN stage (N+ vs. N0) 25% vs. 78% 5.78 (2.66–12.59) 0.000 2.50 (0.96–6.49) 0.060
at second-line treatment (RT/CRT)
recurrent tumor site (others vs.
glottis) 42% vs. 89% 4.70 (1.79–12.33) 0.001 4.77 (1.00–22.70) 0.050
rKPS (≥90% vs. < 90%) 68% vs. 36% 0.55 (0.35–0.84) 0.050
chemotherapy (others vs. cisplatin weekly) 35% vs. 64% 2.37 (1.04–5.45) 0.035
local recurrence after RT
(yes vs. no) 25% vs. 74% 3.10 (1.44–6.67) 0.002 2.63 (1.04–6.69) 0.041
metastases after RT (yes vs. no) 3% vs. 70% 3.44 (1.54–7.71) 0.001
local progression-free survival
at first-line treatment (surgery)
iN stage (N+ vs. N0) 50% vs. 86% 4.52 (1.60–12.72) 0.002 3.62 (0.92–14.19) 0.065
iG stage (G3 vs. G1/2) 59% vs. 82% 2.77 (1.00–7.66) 0.038
at second-line treatment (RT/CRT)
rG stage (G3 vs. G1/2) 59% vs. 82% 2.66 (1.04–7.80) 0.036
EQD2 (> 70 Gy vs. =70 Gy) 90% vs. 68% 0.25 (0.06–1.10) 0.045 0.10 (0.01–0.82) 0.032
chemotherapy (others vs. cisplatin weekly) 46% vs. 86% 5.78 (1.75–19.13) 0.001 3.62 (0.92–14.19) 0.006
distant progression-free survival
at first-line treatment (surgery)
iN stage (N+ vs. N0) 40% vs. 89% 6.19 (1.85–20.76) 0.001 2.56 (1.03–6.34) 0.042
iG stage (G3 vs. G1/2) 65% vs. 85% 3.06 (1.03–9.13) 0.035 3.45 (0.98–12.23) 0.055
at second-line treatment (RT/CRT)
rT stage (T3/4 vs. T1/2) 70% vs. 90% 3.30 (0.91–11.99) 0.055 6.02 (1.29–30.00) 0.028
rG stage (G3 vs. G1/2) 65% vs. 85% 3.12 (1.00–9.25) 0.037 3.45 (0.98–12.23) 0.054
recurrent tumor site (others vs.
glottis) 68% vs. 100% 6.02 (0.68–10.24) 0.014
PTV1 volume (=median vs.
<median of 101 cc) 65% vs. 87% 3.85 (1.04–14.22) 0.030 5.39 (1.65–12.53) 0.038
chemotherapy (others vs. cisplatin weekly) 57% vs. 82% 3.27 (1.03–10.41) 0.034
abbreviations: EQD2 equivalent dose to 2 Gy single fraction, HR hazard ratio, iT stage initial tumor stage, iN stage initial nodal stage, KPS Karnofsky performance
score, RT radiotherapy, CRT chemoradiotherapy, G stage grading stage, rT stage recurrent tumor stage, PTV planning target volume
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lower occurrence of metastases for iN0 stage compared
with iN+ stage (p = 0.042). Increasing N+ stage (N1 vs.
N2 vs. N3) had no impact on DPFS (p = 0.140).
Toxicity
Overall, 20% of the patients reported acute grade 3
(n = 14) and 19% of the patients chronic grade 3 and
grade 4 toxicity (n = 13). During and six weeks after
therapy, no acute grade 4 toxicity could be identified.
An overview of acute and late side effects is shown in
Table 4. Acute grade 3 toxicity consisted of mucositis
(n = 2, 3%), dysphagia (6%, n = 4), odynophagia (n = 5,
7%), dermatitis (n = 4, 6%), xerostomia (n = 1, 1%),
hoarseness (n = 3, 4%) and lymphedema (n = 1, 1%).
Three months after therapy, the majority of the acute
grade 3 side effects disappeared. Nevertheless, 3 patients
received tracheostomy for acute dyspnea due to grade 4
lymphedema of the larynx (4%) and in one patient a laryn-
goesophageal fistula could be diagnosed 6months after
therapy (1%). 3 patients claimed about chronic severe dys-
phagia with high-grade stenosis of the laryngoesophageal
junction with the need of regular bougienage up to the last
follow-up (4%). Further, one patient developed a laryngo-
cutaneous fistula 12months after RT (1%) and one patient
developed a wound healing disorder in radiation field 24
months after therapy (1%).
Under RT, 43% of the patients needed supportive nu-
trition for nutritional difficulties due to acute side ef-
fects (n = 30). Acute gastric tube dependence counted
34% (n = 24). 3 to 6 months after therapy, only 13% of
the patients needed farther a gastric tube for nutrition
(n = 9). Only one patient was dependent on a gastric
tube for more than 2 years (1%).
Discussion
Findings
The majority of the patients in the current analysis
were treated with dose-escalated RT (93%) and con-
comitant cisplatin weekly chemotherapy (60%) for
recurrent laryngeal or hypopharyngeal SCC after first-
line treatment with surgery alone. Two thirds of the
patients had tumors in advanced stages (UICC III and
IV) before treatment. Nevertheless, we identified an
excellent 3-year LPFS, OS and DPFS of 75, 76 and
85% and an estimated 5-year LPFS, OS and DPFS of
75, 64 and 82%, respectively. The 5-year local control
rate was 79% for this unfavourable patient population.
All recurrences occurred in-field and within the first
Fig. 1 LPFS depends significantly on the use of concomitant systemic therapy with survival benefit for patients receiving cisplatin weekly
chemotherapy vs. others (carboplatin/5-fluoruracil and cetuximab) (p = 0.006). 5-year LPFS amounts 86% vs. 43% for patients who received
concomitant cisplatin weekly vs. patients who did not
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two years after treatment. Larynx-preservation could
be observed in 90% of the patients who received
organ-preserving surgery as initial treatment. Local
control was best achieved in patients receiving an
EQD2 > 70 Gy on the macroscopic tumor and con-
comitant chemotherapy with cisplatin weekly. RT dose
and the use of cisplatin chemotherapy did not correl-
ate with patients’ KPS (p = 0.139). OS depended nega-
tively on the occurrence of local recurrences after
salvage RT and on the recurrent tumor site before RT
with survival benefit for recurrent tumors involving
the glottis. DPFS differed significantly regarding recur-
rent tumor size and the initial nodal stage. Overall,
compliance was well (93%) and RT was tolerated with
moderate toxicity.
Survival results
Nowadays, CRT is seen as an equivalent therapy option
to surgery regarding tumor control in laryngeal and
hypoharyngeal tumors [11, 12]. Thus, Mendenhall et al.
reported 2001 RT alone for T1/2 N0 larynx tumors as an
alternative curative therapy option to surgery with a
comparable 5-year LPFS of 72 to 94% depending on T
stage, a 5-year OS of 79% and a 5-year DPFS of 98%
[13]. Nevertheless, surgery in form of organ-preserving
endoscopic resection, laser surgery or open-neck partial
laryngectomy is still considered as the gold standard in
the treatment of early stage tumors with local control
rates of 60 to 95%, declining with increasing T stage
[12]. While local relapses are relatively rare after primary
treatment of early stage tumors, local control in ad-
vanced hypopharyngeal and laryngeal tumors remains a
challenge. As organ-preserving treatment strategies are
increasingly used as first-line treatment, the use of
organ-preserving RT in combination with chemotherapy
for advanced stages gained in importance within the last
decades [5, 13, 14]. However, 40 to 60% of patients with
advanced tumors relapse after primary CRT [5, 15]. Sal-
vage treatment options for these patients are limited, as
re-irradiation is mostly limited by the tumor site and the
necessary prescription dose to the recurrent tumor. In
these cases, salvage surgery is mostly required. The ef-
fectiveness of salvage surgery after failure of primary CRT
(2-year OS between 27 and 71%) is reported by several
studies [16–18]. Taguchi et al. reported a 5-year OS and
disease-specific survival of 61 and 66% for salvage surgery
after primary CRT vs. 10 and 10% for patients who failed
primary CRT but did not undergo salvage surgery [18].
While poor prognosis with a 5-year OS of 16% is de-
scribed for recurrent hypopharyngeal tumors after salvage
Fig. 2 LPFS depends significantly on the applied RT dose with survival benefit for patients receiving an EQD2 > 70 Gy (p = 0.032). Patients who
received an EQD2 > 70 Gy show a 5-year LPFS of 90% vs. 68% compared with patients who received an EQD2≤ 70 Gy
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Table 4 Overview of acute and chronic toxicity (n = 70)
characteristic acute toxicity (n = 70) chronic toxicity (n = 63)
No. (%) No. (%)
under RT and 6 weeks post RT 3–6 months post RT 12 months post RT 24months post RT at last follow-up
toxicity
grade 1 10 (14) 19 (27) 22 (31) 23 (33) 17 (24)
grade 2 39 (56) 21 (30) 10 (14) 6 (9) 5 (7)
grade 3 14 (20) 4 (6) 3 (4) 3 (4) 3 (4)
grade 4 0 4 (6) 1 (1) 1 (1)
dysphagia
grade 1 6 (9) 7 (10) 6 (9) 6 (9) 5 (7)
grade 2 28 (40) 4 (6) 5 (7) 1 (1) 0
grade 3 4 (6) 3 (4) 3 (4) 3 (4) 3 (4)
odynophagia
grade 1 8 (11) 1 (1) 0 0 0
grade 2 14 (20) 0 0 0 0
grade 3 5 (7) 0 0 0 0
mucositits
grade 1 12 (17) 1 (1) 0 0 0
grade 2 36 (51) 0 0 0 0
grade 3 2 (3) 0 0 0 0
dermatitis
grade 1 19 (27) 2 (3) 0 0 0
grade 2 18 (26) 1 (1) 0 0 0
grade 3 4 (6) 0 0 0 0
xerostomia
grade 1 32 (46) 30 (43) 17 (24) 13 (19) 10 (14)
grade 2 12 17 () 4 (6) 2 (3) 2 (3) 2 (3)
grade 3 1 (1) 0 0 0 0
hoarseness
grade 1 16 (23) 15 (21) 13 (19) 12 (17) 10 (14)
grade 2 13 (19) 7 (10) 3 (4) 1 (1) 2 (3)
grade 3 3 (4) 1 (1) 1 (1) 1 (1) 0
fatigue
grade 1 6 (9) 3 (4) 2 (3) 1 (1) 1 (1)
grade 2 6 (9) 2 (3) 1 (1) 0 0
dysgeusia
grade 1 11 (16) 14 (20) 11 (16) 8 (11) 7 (10)
grade 2 20 (29) 4 (6) 0 0 0
dry cough
grade 1 7 (10) 5 (7) 2 (3) 2 (3) 0
grade 2 1 (1) 0 0 0 0
lymphedema
grade 1 6 (9) 12 (17) 2 (3) 1 (1) 1 (1)
grade 2 8 (11) 2 (3) 1 (1) 1 (1) 4 (6)
grade 3 1 (1) 1 (1) 1 (1) 1 (1) 1 (1)
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surgery, the same treatment method offers 5-year OS rates
ranging from 57 to 70% for recurrent laryngeal tumors
[19–21]. Recurrent hypopharyngeal tumors are mostly
considered inoperable and should, therefore, be treated
with alternative salvage methods [22]. Salvage CRT is gen-
erally reserved for recurrent tumors after primary total
laryngectomy, for patients with inoperable recurrent
tumors or in cases, where the patient rejects total laryn-
gectomy as the only remaining treatment option in order
to further preserve the organ function. Patients who re-
ceive salvage CRT mostly appear with initially early stage
tumors and represent a non-comparable patient collective
to patients who receive salvage surgery after failure of pri-
mary CRT. Nevertheless, studies describing a homoge-
neous patient population after salvage CRT including
recurrent hypopharyngeal and laryngeal tumors only are
lacking. Lee et al. reported a 2-year OS and progression-
free survival of 74 and 68% for patients with recurrent
hypopharyngeal and laryngeal tumors who underwent dif-
ferent salvage treatment methods, i.e. salvage surgery with
or without RT, RT alone, chemotherapy alone, after differ-
ent initial treatments, i.e. CRT for advanced tumors or pri-
mary surgery for early stage tumors [23]. Li et al.
analysed patients who were initially treated with sur-
gery, RT or CRT for recurrent laryngeal tumors. The
patients received salvage treatment with surgery for op-
erable recurrent tumors in 54% and radiation in 16% of
the cases [24]. Salvage surgery resulted in a 5-year OS
rate of 73% vs. 32% for other salvage treatment
methods like RT, while the high OS rate for salvage sur-
gery and the decreased OS of salvage RT were dis-
cussed via patient selection bias (operable tumors,
initial tumor stage). This could be a valuable reason for
the excellent survival results in the current analysis as
well, as the majority of our patients had initially early
stage tumors (56% UICC I/II). Nevertheless, survival
analysis showed no significant difference in the LPFS,
OS and DPFS for initially early stage and initially ad-
vanced tumors.
Prognostic factors
Several meta-analyses and randomized studies have
proven the beneficial role of concomitant chemotherapy
in combination with RT, especially regarding cisplatin
chemotherapy, showing superior local control and OS
rates in laryngeal/hypopharyngeal tumors as well as in
other HNC either in the primary or postoperative setting
[5, 15, 25–27]. Besides an EQD2 > 70 Gy achieved by
using fractionation doses >2Gy, we could identify a sig-
nificant impact of cisplatin chemotherapy on LPFS only
[28, 29]. Nevertheless, Pignon et al. could show in the
MACH-NC meta-analysis that chemotherapy with car-
boplatin and 5-fluoruracil is considered to be equivalent
to cisplatin chemotherapy. The results of the current
study could possibly be explained by patient selection
bias between both groups [30]. In the current literature,
further factors influencing LPFS, i.e. T stage, N stage, G
stage, sex, age, vocal cord invasion, overall treatment
time and RT field size are discussed in the first-line
treatment [13, 31–34]. Glottic tumors seem to have a
survival benefit compared with other tumor sites, thus
in several studies superior OS rates are described [17–
20]. The occurrence of local recurrence after treatment,
tumor size and N stage are accepted as further prog-
nostic factors [31–35]. For second-line treatment,
initial tumor in the hypopharynx vs. the larynx, recur-
rent tumor in the hypopharynx vs. the larynx, advanced
primary tumor, advanced recurrent tumor, advanced
primary N stage and advanced initial and recurrent G
stage were most frequently associated with decreased
progression-free survival resulting in a poor prognosis
[23, 24, 36]. In multivariate analysis, we could not iden-
tify an impact of tumor size and N stage on OS,
possibly due to the low patient number but on DPFS.
Thus, tumors with initial N+ stage and increased recur-
rent tumor size (PTV1, rT stage) influenced distant
control negatively [34]. Additionally, tumor differenti-
ation (G stage) can be considered as further prognostic
factor regarding DPFS [31].
Table 4 Overview of acute and chronic toxicity (n = 70) (Continued)
characteristic acute toxicity (n = 70) chronic toxicity (n = 63)
No. (%) No. (%)
under RT and 6 weeks post RT 3–6 months post RT 12 months post RT 24months post RT at last follow-up
grade 4a 0 3 (4) 0 0 0
fistula
laryngoesophageal 0 1 (1) 0 0 0
laryngocutaneous 0 0 1 (1) 0 0
wound healing disorder 0 0 0 1 (1) 0
gastric tube dependence 24 (34) 9 (13) 5 (7) 1 (1) 1 (1)
abbreviations: RT radiotherapy
awith tracheotomy for acute dyspnea
Akbaba et al. Radiation Oncology           (2019) 14:34 Page 9 of 12
Toxicity
Superior dose conformity and decreased toxicity due to
improved preservation of organs at risk compared with
3D-RT is described for IMRT [37–40]. Nevertheless, tox-
icity after IMRT remains high [41–45]. Especially in the
hypopharynx and larynx region, significant higher rates of
late side effects occur due to the proximity of several
organs at risk compared with other regions of the head
and neck [45]. For patients treated with concurrent CRT,
Forastiere et al. could show in the RTOG trial 91–11 a
high rate of severe late grade 3 and 4 toxicity, especially
regarding mucositis (43%) [44]. In a RTOG analysis of
three RTOG trials (RTOG 91–11, RTOG 97–03, RTOG
99–14), Machtay et al. identified 43% late side effects after
CRT for locally advanced squamous cell carcinoma of the
head and neck, and described grade 3 and 4 pharyngeal
and laryngeal dysfunction in 39%, gastric tube dependence
longer than 2 years in 13% and treatment-related death
within 3 years in 10% of the patients. Swallowing limita-
tions, aspiration, laryngoesophageal stricture and dyspha-
gia dominated regarding laryngoesophageal dysfunction
[45]. Caudell et al. reported a 3-year laryngoesophageal
dysfunction-free survival (LEDFS) of 32% for patients who
were treated with CRT for advanced SCC of the larynx
and hypopharynx [42]. For salvage treatment methods as
well, high toxicity rates are reported. Several authors
described complication rates between 44 and 59% for sal-
vage surgery after first-line CRT [16, 17, 46]. A systematic
review and meta-analysis of the complications of salvage
total laryngectomy including 3293 patients by Hasan et al.
showed a complication rate of 68% with 29% pharyngocu-
taneous fistula [47].In the current analysis, in contrast,
only 19% of the patients claimed about severe chronic tox-
icity. Especially laryngoesophageal dysfunction consisting
of severe dysphagia (4%), fistula (3%), dyspnea (4%) or
wound healing disorder (1%) were observed. Only one
patient showed feeding tube dependence over 2 years after
RT (1%). We could not identify any treatment-related
deaths within the follow-up time. Despite first-line surgery
and second-line dose-escalated RT, we identified moderate
toxicity rates making salvage CRT after failed surgery a
safe therapy alternative.
Conclusion
Salvage radiotherapy is an effective curative therapy op-
tion for recurrent hypopharyngeal and laryngeal SCC after
prior surgery with excellent local control rates and moder-
ate toxicity comparable to prior results concerning
primary radiotherapy. We recommend dose-escalated
IMRT with an EQD2 > 70Gy as well as the use of con-
comitant cisplatin weekly chemotherapy for superior
LPFS. Nevertheless, patient selection for curative salvage
treatment remains challenging.
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